<DOC>
	<DOCNO>NCT00014937</DOCNO>
	<brief_summary>ACTG 388 clinical trial compare three- four-drug anti-HIV drug regimen demonstrate effectiveness three-drug regimen . This study compare ability two different three-drug anti-HIV drug regimen reduce level HIV blood . The study also evaluate whether patient discontinue regimens drug side effect .</brief_summary>
	<brief_title>Simplified Drug Regimens HIV Patients ACTG 388 Patients Who Responded A First Potent Combination Regimen</brief_title>
	<detailed_description>ACTG 388 design evaluate two four-drug regimen compare three-drug regimen patient relatively treatment naive . Based increased complexity toxicity four-drug regimen resultant negative impact response compare three-drug regimen , study evaluate simplified potent regimen appear warrant . This study evaluate simpilified drug regimen design enhance virologic activity without necessarily increase number antiretroviral drug . The study regimens assessed virologic control tolerability . The study population include patient previously enrol ACTG 388 patient prior advanced HIV disease receive responded potent antiretroviral therapy without evidence virologic relapse . Patients stratify accord ACTG 388 treatment non-ACTG 388 study participation . Patients randomize receive either protease inhibitor ( PI ) -sparing regimen 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) efavirenz ( EFV ) ( Arm I ) NRTI-sparing regimen EFV lopinavir/ritonavir ( LPV/r ) ( Arm II ) . Arm I option enteric-coated didanosine ( ddI-EC ) plus lamivudine ( 3TC ) , ddI-EC plus zidovudine ( ZDV ) , ZDV plus 3TC ( Combivir ) , stavudine ( d4T ) plus 3TC , ddI-EC plus d4T ( exception note protocol ) . Only LPV/r , EFV , d4T , ddI provide study ; medication obtain nonstudy prescription . All patient evaluate safety virologic immunologic response Weeks 4 8 , every 8 week study end . In addition , patient assessment fat redistribution , fast lipid profile , fast insulin level , venous lactate level , treatment adherence . Patients follow 1.5 3 year . Interim safety analysis conduct June 2002 June 2003 . Patients study may also enroll A5125s , fat distribution bone mineral density substudy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria ACTG 388 Participants HIV1 RNA level &lt; = 200 copies/ml within 70 day study entry Stable antiHIV drug plan without harmful drug side effect serious illness time study entry Inclusion Criteria NonACTG 388 Participants Potent antiHIV drug regimen first HIV treatment least 18 month HIV1 RNA level &gt; = 80,000 copies/ml CD4+ count &lt; = 200 cells/mm3 prior start antiHIV drug regimen HIV1 RNA level &lt; = 400 copies/ml ( le 500 copies/ml bDNA ) within 32 week initial therapy HIV1 RNA level &lt; = 200 copies/ml within 60 day study entry Inclusion Criteria Both ACTG 388 NonACTG 388 Participants Acceptable method contraception Consent parent legal guardian 18 year age Exclusion Criteria ACTG 388 Participants Viral resistance study drug determine resistance study ACTG 388 Exclusion Criteria ACTG 388 NonACTG 388 Participants Pregnancy breastfeed Certain heart medicine ( flecainide propafenone ) ; antihistamine ( astemizole terfenadine ) ; rifampin ; ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) ; intestinal agent ( cisapride ) ; herbal product ( St. John 's wort ) ; lovastatin simvastatin ; neuroleptic ( pimozide ) ; sedatives/hypnotics ( midazolam triazolam ) Allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>ABT 378</keyword>
	<keyword>Combivir</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>